Literature DB >> 28368378

Sinusoidal obstructive syndrome prophylaxis with recombinant human soluble thrombomodulin is feasible in gemtuzumab ozogamicin-treated patients undergoing allogeneic hematopoietic cell transplantation.

S Yamamoto1, R Matsuno1, Y Sugishita1, R Kaneko1, N Okamoto1, M Koganesawa1, S Fujita1, K Akiyama1, D Toyama1, K Isoyama1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28368378     DOI： 10.1038/bmt.2017.65

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN： 0268-3369            Impact factor:   5.483


× No keyword cloud information.
  15 in total

1.  Successful treatment of sinusoidal obstructive syndrome after hematopoietic stem cell transplantation with recombinant human soluble thrombomodulin.

Authors:  T Ikezoe; K Togitani; N Komatsu; M Isaka; A Yokoyama
Journal:  Bone Marrow Transplant       Date:  2009-08-31       Impact factor: 5.483

2.  Can recombinant thrombomodulin play a preventive role for veno-occlusive disease after haematopoietic stem cell transplantation?

Authors:  S Nomura; R Ozasa; T Nakanishi; S Fujita; M Miyaji; S Mori; T Yokoi; T Ito; K Ishii
Journal:  Thromb Haemost       Date:  2011-04-07       Impact factor: 5.249

3.  Defibrotide for prophylaxis of hepatic veno-occlusive disease in paediatric haemopoietic stem-cell transplantation: an open-label, phase 3, randomised controlled trial.

Authors:  Selim Corbacioglu; Simone Cesaro; Maura Faraci; Dominique Valteau-Couanet; Bernd Gruhn; Attilio Rovelli; Jaap J Boelens; Annette Hewitt; Johanna Schrum; Ansgar S Schulz; Ingo Müller; Jerry Stein; Robert Wynn; Johann Greil; Karl-Walter Sykora; Susanne Matthes-Martin; Monika Führer; Anne O'Meara; Jacek Toporski; Petr Sedlacek; Paul G Schlegel; Karoline Ehlert; Anders Fasth; Jacek Winiarski; Johan Arvidson; Christine Mauz-Körholz; Hulya Ozsahin; Andre Schrauder; Peter Bader; Joseph Massaro; Ralph D'Agostino; Margaret Hoyle; Massimo Iacobelli; Klaus-Michael Debatin; Christina Peters; Giorgio Dini
Journal:  Lancet       Date:  2012-02-23       Impact factor: 79.321

4.  Efficacy and safety of recombinant human soluble thrombomodulin (ART-123) in disseminated intravascular coagulation: results of a phase III, randomized, double-blind clinical trial.

Authors:  H Saito; I Maruyama; S Shimazaki; Y Yamamoto; N Aikawa; R Ohno; A Hirayama; T Matsuda; H Asakura; M Nakashima; N Aoki
Journal:  J Thromb Haemost       Date:  2006-10-13       Impact factor: 5.824

5.  A domain composed of epidermal growth factor-like structures of human thrombomodulin is essential for thrombin binding and for protein C activation.

Authors:  K Suzuki; T Hayashi; J Nishioka; Y Kosaka; M Zushi; G Honda; S Yamamoto
Journal:  J Biol Chem       Date:  1989-03-25       Impact factor: 5.157

Review 6.  Management of hepatic sinusoidal obstruction syndrome following treatment with gemtuzumab ozogamicin (Mylotarg).

Authors:  George B McDonald
Journal:  Clin Lymphoma       Date:  2002-03

7.  The syndrome of hepatic veno-occlusive disease after marrow transplantation.

Authors:  S I Bearman
Journal:  Blood       Date:  1995-06-01       Impact factor: 22.113

8.  BCSH/BSBMT guideline: diagnosis and management of veno-occlusive disease (sinusoidal obstruction syndrome) following haematopoietic stem cell transplantation.

Authors:  Fiona L Dignan; Robert F Wynn; Nedim Hadzic; John Karani; Alberto Quaglia; Antonio Pagliuca; Paul Veys; Michael N Potter
Journal:  Br J Haematol       Date:  2013-09-17       Impact factor: 6.998

9.  Veno-occlusive disease of the liver and multiorgan failure after bone marrow transplantation: a cohort study of 355 patients.

Authors:  G B McDonald; M S Hinds; L D Fisher; H G Schoch; J L Wolford; M Banaji; B J Hardin; H M Shulman; R A Clift
Journal:  Ann Intern Med       Date:  1993-02-15       Impact factor: 25.391

10.  Revised diagnosis and severity criteria for sinusoidal obstruction syndrome/veno-occlusive disease in adult patients: a new classification from the European Society for Blood and Marrow Transplantation.

Authors:  M Mohty; F Malard; M Abecassis; E Aerts; A S Alaskar; M Aljurf; M Arat; P Bader; F Baron; A Bazarbachi; D Blaise; F Ciceri; S Corbacioglu; J-H Dalle; F Dignan; T Fukuda; A Huynh; T Masszi; M Michallet; A Nagler; M NiChonghaile; S Okamoto; A Pagliuca; C Peters; F B Petersen; P G Richardson; T Ruutu; B N Savani; E Wallhult; I Yakoub-Agha; R F Duarte; E Carreras
Journal:  Bone Marrow Transplant       Date:  2016-05-16       Impact factor: 5.483
View more
  2 in total

Review 1.  Gemtuzumab ozogamicin and novel antibody-drug conjugates in clinical trials for acute myeloid leukemia.

Authors:  Bo Yu; Delong Liu
Journal:  Biomark Res       Date:  2019-10-31

2.  Successful Treatment of Pediatric Refractory/Relapsed AML with KIR-Ligand-Mismatched Cord Blood Transplant after FLAG-IDA Reinduction Therapy with or without the GO Regimen.

Authors:  Daisuke Toyama; Ryosuke Matsuno; Yumiko Sugishita; Ryota Kaneko; Naoko Okamoto; Masaya Koganesawa; Sachio Fujita; Kosuke Akiyama; Keiichi Isoyama; Shohei Yamamoto
Journal:  Case Rep Hematol       Date:  2020-02-12
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.